Application of tegafur gimer, docetaxel and carboplatin in head and neck squamous cell carcinoma therapy.

Squamous cell carcinoma, in the clinical manifestation, is a form of cancer derived from lesions of keratinocytes of epidermis or accessories such as sebaceous ducts, hair follicles, sweat glands, etc. The disease is more common in older men, with prone locations at patients' scalp, face, neck and arms and other exposed parts. Head and neck squamous cell carcinoma (HNSCC) causes a serious impact on patients' daily life, making patients suffer from double blow in mental and physical aspects and reducing patients' life quality. To find effective treatment method for HNSCC, our hospital studies clinical effects of combination therapy of tegafur gimer, docetaxel and carboplatin for the disease. By way of grouping research, therapeutic effect of such treatment and adverse reactions were assessed and analyzed. The study clearly and fully confirms effectiveness of combination therapy of tegafur gimer, docetaxel and carboplatin for HNSCC.

Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines.

Previous studies have demonstrated that pluripotency-associated transcription factors, such as Oct3/4, Nanog and Sox2, play a crucial role in the development and malignant progression of various types of tumors. Breast cancer is the most frequent cancer among females, being a heterogeneous disease, with distinct morphologies, metastatic behavior and therapeutic responses. The expression of Oct3/4, Nanog and Sox2 in 3 human breast cancer cell lines, MCF7, T-47D and MDA-MB-231, was determined. The expression of Oct3/4, Nanog and Sox2 mRNA was determined by reverse transcription polymerase chain reaction (RT-PCR) and protein expression was detected by immunocytohistochemistry. RT-PCR revealed that all three human breast cancer cell lines tested expressed evident Oct3/4, Nanog and Sox-2 mRNA at various levels. Higher levels of Oct3/4 were identified in MCF7 and MDA-MB-231 cells compared with T-47D cells. Higher levels of Nanog were observed in MCF7 and T-47D cells compared with MDA-MB-231 cells and the highest expression of Sox-2 was detected in MCF7 cells. The nuclear localization of Oct3/4, Nanog and Sox-2 was confirmed by immunostaining. Oct3/4, Nanog and Sox2 were expressed in human breast cancer cell lines. Further studies are required to characterize the role of Oct3/4, Nanog and Sox2 in human breast cancer.